PharmaStem Therapeutics Overview
- Year Founded
-
1985

- Status
-
Private
- Latest Deal Type
-
2ndary - Private
PharmaStem Therapeutics General Information
Description
Provider of research and development services intended for stem cell preservation. The company specializes in the study of the development of umbilical cord and placental blood preservation for the treatment of cancers, immune-specific diseases and gene therapy, enabling patients to get required medical assistance.
Contact Information
Website
www.pharmastem.comCorporate Office
- 69 Prospect Avenue
- Larchmont, NY 10538
- United States
Corporate Office
- 69 Prospect Avenue
- Larchmont, NY 10538
- United States
PharmaStem Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Secondary Transaction - Private | 29-Jul-2024 | Completed | Generating Revenue | |||
1. Early Stage VC | Completed | Generating Revenue |
PharmaStem Therapeutics Comparisons
Industry
Financing
Details
PharmaStem Therapeutics Competitors (5)
One of PharmaStem Therapeutics’s 5 competitors is Mesoblast, a Corporation company based in Melbourne, Australia.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Mesoblast | Corporation | Melbourne, Australia | ||||
Celltex Therapeutics | Formerly VC-backed | Houston, TX | ||||
Lisata Therapeutics | Corporate Backed or Acquired | Basking Ridge, NJ | ||||
GENECELL INTERNATIONAL | Corporation | Miami, FL | ||||
Brainstorm Cell Therapeutics | Corporation | New York, NY |
PharmaStem Therapeutics Patents
PharmaStem Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
DE-3855301-D1 | Insulation and preservation of foetal and neonatal hematopoietic stem and progenitor cells of the blood | Inactive | 12-Nov-1987 | ||
DE-3855301-T2 | Insulation and preservation of foetal and neonatal hematopoietic stem and progenitor cells of the blood | Inactive | 12-Nov-1987 | ||
CA-1341587-C | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood | Inactive | 12-Nov-1987 | ||
AU-2610288-A | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood | Inactive | 12-Nov-1987 | ||
US-6461645-B1 | Cryopreserved pharmaceutical composition comprising viable human neonatal or fetal hematopoietic stem cells derived from umbilical cord or placental blood of single human collected at birth, cryopreservative, carrier | Inactive | 12-Nov-1987 | C12N5/0647 |
PharmaStem Therapeutics FAQs
-
When was PharmaStem Therapeutics founded?
PharmaStem Therapeutics was founded in 1985.
-
Where is PharmaStem Therapeutics headquartered?
PharmaStem Therapeutics is headquartered in Larchmont, NY.
-
What industry is PharmaStem Therapeutics in?
PharmaStem Therapeutics’s primary industry is Biotechnology.
-
Is PharmaStem Therapeutics a private or public company?
PharmaStem Therapeutics is a Private company.
-
What is PharmaStem Therapeutics’s current revenue?
The current revenue for PharmaStem Therapeutics is
. -
Who are PharmaStem Therapeutics’s competitors?
Mesoblast, Celltex Therapeutics, Lisata Therapeutics, GENECELL INTERNATIONAL, and Brainstorm Cell Therapeutics are competitors of PharmaStem Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »